Atlas Trials

Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

Clinical trial NCT06977061 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06977061
Sponsor
Queling Liu
Status
NOT_YET_RECRUITING
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Gastric Neoplasm
Start date
2025-06-01
Primary completion
2026-06-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.